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The development of effective strategies against cervical cancer in Africa requires accurate type specific data on human papillomavirus
(HPV) prevalence, including determination of DNA sequences in order to maximise local vaccine efficacy. We have investigated
cervical HPV infection and squamous intraepithelial lesions (SIL) in an unselected cohort of 1061 women in a rural Gambian
community. Squamous intraepithelial lesions was diagnosed using cytology and histology, HPV was typed by PCR-ELISA of DNA
extracts, which were also DNA sequenced. The prevalence of cervical HPV infection was 13% and SIL were observed in 7% of
subjects. Human papillomavirus-16 was most prevalent and most strongly associated with SIL. Also common were HPV-18, -33, -58
and, notably, -35. Human papillomavirus DNA sequencing revealed HPV-16 samples to be exclusively African type 1 (Af1). Subjects
of the Wolof ethnic group had a lower prevalence of HPV infection while subjects aged 25–44 years had a higher prevalence of
cervical precancer than older or younger subjects. This first report of HPV prevalence in an unselected, unscreened rural population
confirms high rates of SIL and HPV infection in West Africa. This study has implications for the vaccination of Gambian and other
African populations in the prevention of cervical cancer.
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It is well established, on a cellular and epidemiological basis, that the
sexual transmission of high oncogenic risk (HR) human papilloma-
virus (HPV) types is the essential prerequisite for cervical
carcinogenesis (zur Hausen, 1977; IARC_Monographs, 1995; Mun ˜oz
and Bosch, 1996; Walboomers et al, 1999). Cervical cancer is the
most common malignancy in West African women (Koulibaly et al,
1997; Bah et al, 2001) but accurate, population-based HPV
prevalence data are lacking. Many therapeutic and prophylactic
vaccines against HPV infection are in development, with some now
entering phase III trials (Bosch et al, 2001; Nardelli-Haefliger et al,
2003; Taira, 2004; Tomson et al, 2004; Christensen, 2005; Gravitt and
Shah, 2005; Maclean et al, 2005). Such vaccines are essential in
developing countries where 80% of new cervical cancer cases occur
but where screening and treatment of precancerous lesions is not
available (Kitchener and Symonds, 1999; Lazcano-Ponce et al, 1999).
Risk factors in the spread of genital HPV infection vary between
populations, and include genetic variation in human leukocyte
antigen (HLA) types resulting in differential susceptibility to HPV
infection and socio-demographic factors such as sexual behaviour or
age (Burk et al, 1996; Koutsky, 1997; Svare et al, 1998; Herrero,
1999). Consequently, prevalence of cervical cancer in industrialised
nations cannot be assumed to apply in the developing world; local
characterisation of HPV patterns is essential. Human papilloma-
virus-16 is the most prevalent type in cervical cancers worldwide
(Bosch et al, 1995b), although regional variation in
HR HPV types does occur (Bosch et al, 1995a; Herrero et al,2 0 0 0 ;
Castellsague et al, 2001; Mayaud et al,2 0 0 1 ;X iet al, 2003). HPV
DNA sequence must therefore be defined to ensure vaccine efficacy
and prevent the selective emergence of rare, virulent variants.
Here we describe such detailed HPV analysis in a rural Gambian
community, presenting the largest point-prevalence study to date in
a rural unselected sub-Saharan African population.
METHODS
Population
Samples were collected during a large reproductive morbidity
survey in rural Gambia between January and July 1999 as
described elsewhere (Walraven et al, 2001). Briefly, the MRC has
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surrounding the provincial town of Farafenni since 1981. All
women aged 15–54 years in 20 of these villages were approached
and invited to participate. The study was approved by the ethics
committee of The Gambian Government/MRC Laboratories (SCC
proposal 755). All work was conducted in accordance with the
Helsinki Declaration of 1975 as revised in 1983. After obtaining
informed consent. A total of 1348 women (72% of those eligible)
were seen and examined in dedicated village clinics.
Sampling
As part of the full gynaecological assessment, all consenting
subjects who did not have an intact hymen underwent a vaginal
speculum examination (Figure 1). Cervical smears were taken with
an Aylesbury spatula for cytology (Wolfendale et al, 1987) fixed,
stored and transported to Cardiff. Human papillomavirus
sampling was performed by inserting the brush-sampler into
the cervical canal and rotating it through 3601. This brush was
placed in transport medium immediately (Digene Corporation,
Gaithersburg, MD, USA), stored at  701C and frozen samples
transported to Cardiff for analysis.
Cytology
Women with abnormalities were offered further assessment and
treatment with Large Loop Excision of the Transformation Zone
(LLETZ) or knife cone biopsy. Histology and cytology results
Intact hymen
80 (27%)
Refused exam
207 (63%)
High risk
93 (89%)
Inadequate
111 (11%)
Questionnaire and serum only
287 (21%)
Eligible female population
1871
Pelvic exam and cervical samples
1061 (79%)
Recruited
1348 (72%)
PCR
934 (88%)
Adequate
946 (89%)
SIL
63 (7%)
Cytology
1057 (99%)
-Globin +ve
710 (76%)
-Globin −ve
224 (24%)
Low risk
12(11%)
Typed by ELISA
93 (96%)
HPV +ve
104 (15%)
HPV −ve
606 (85%)
Typed by sequencing
4 (4%)
Identified
97 (93%)
Unidentified
7 (7%)
Total infections = 101
(Inc. 16 samples with
dual HPV infection)
Abnormal cytology
70 (7%)
Figure 1 Overview of gambia reproductive morbidity study.
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low- or high-grade squamous intraepithelial lesions (LSIL or HSIL)
(NCI_Workshop, 1989), microinvasive or invasive carcinoma of
the cervix.
Human papillomavirus detection and typing
DNA was extracted from cervical brush samples by freeze–thaw
from  701C, boiling for 10min followed by rapid cooling on ice.
Human papillomavirus DNA was detected by PCR using the
consensus HPV primers GP5þ and GP6þ (biotinylated) (Jacobs
et al, 1997). In tandem, for each sample a PCR was also set up to
amplify the human b-globin gene in order to verify the presence of
an adequate DNA sample and the absence of PCR inhibitors. The
presence of HPV and b-globin DNA was visualised on an agarose
gel. Human papillomavirus typing was preformed by enzyme
linked immuno-sorbent assay (ELISA) using streptavidin coated
microtitre plates to capture PCR product (Jacobs et al, 1997).
Initially, this involved two cocktails of digoxigenin labelled probes,
the first including those types commonly associated with cervical
cancer (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59,
-66 and -68). The second cocktail included those types associated
with benign genital lesions (HPV-6, -11, -40, -42, -43 and -44).
Detection was performed using an alkaline phosphatase conju-
gated antidigoxigenin fab fragment. If positive for either of the two
probes, a further ELISA was performed using the full spectrum of
relevant (HR) or low risk (LR) individual probes.
Sequencing
Samples that could not be identified by ELISA were characterised
by DNA sequencing. Selected HPV positive samples were also
sequenced to confirm typing accuracy and to detect any relevant
sequence variations in known HPV types. Sequencing was carried
out on a Beckman Coulter CEQ2000 Automated Sequencer, using
protocols and reagents supplied by the manufacturer. Human
papillomavirus DNA sequencing utilised the MY09/MY11 con-
sensus primer pair as the product of these (E455bp) is a more
suitable target for sequencing than that of GP5þ/6þ (E140bp).
Furthermore, MY09/11 primers amplify a region containing highly
conserved amino acids, which simplifies sequence alignment in
HPV classification (Chan et al, 1995). An NCBI BLAST (http://
www.ncbi.nlm.nih.gov/BLAST/) search was carried out for each
of the consensus strands produced by sequencing at least twice
in each direction. Alignment analysis was carried out using the
Lasergene suit of software (DNA* Inc., Madison, WI, USA). The
sequences most homologous to the Gambia samples are listed
in Table 2 with the percentage DNA similarity and number of
differences in both amino acids (coding) and DNA only
(noncoding) in the MY9/11 amplified region between the Gambia
samples and the closest BLAST hits.
Statistical analysis
All data were double-entered, checked and cleaned using Epi-Info
6.4 with subsequent analysis performed in STATA 7 (Statacorp.
Texas). Frequency distributions of HPV infection and different
HPV types were calculated. Socio-demographic characteristics
and other morbidities were examined as risk factors for HPV
infection by cross tabulation and w
2 tests. To adjust for any
confounding effects, each potential risk factor was included in a
logistic regression model with age group, marital status and ethnic
group. The same procedure was followed for SIL. There were
significant differences in the distribution of ethnic groups between
the sample and the eligible population and differing disease
prevalence between ethnic groups (Table 1). An adjusted
prevalence was therefore calculated using the prevalence within
each ethnic group and the distribution of ethnic groups in the
eligible population.
RESULTS
Of 1871 eligible women, 1348 (72%) participated in the study
(Figure 1) and 1061 women consented to full gynaecological
examination. Of participants aged 15–24 years, 30.7% (147 out
of 478) were unmarried, 80 of whom consented to intimate
examination and had an intact hymen (Figure 1). These women
were not examined internally by speculum and no cervical
specimen was collected. No HPV sample was taken from a further
64 women examined by speculum and 63 samples were lost in
transit. The b-globin human housekeeping gene was amplified in
710 out of 934 (76%) samples; consequently, only these samples
were suitable for HPV analysis. The b-globin negative samples may
have been incorrectly stored or damaged during transfer to the
UK, prevalence figures are therefore based upon the 710 b-globin
positive samples. Of the three main ethnic groups, Wolof women
were slightly under-represented (38.7% of eligible population vs
32.1% of those with adequate cytology and 34.1% of those with
adequate HPV samples) and Mandinka women were slightly
over-represented (43.9% of eligible population vs 49.5% of those
with adequate cytology and 46.2% of those with adequate HPV
samples). Younger women aged 15–24 years were under-
represented (27.9 and 25.9% in those with adequate cytology and
adequate HPV samples, respectively, compared with 39.1% in the
eligible population).
Human papillomavirus prevalence
Human papillomavirus infection was present in 95 of 710 adequate
samples (crude prevalence 13.4% (95% CI: 10.96–16.11%)).
Adjusting HPV prevalence for under-representation of Wolof
subjects reduced prevalence slightly to 13.0%. Human papilloma-
virus typing by PCR-ELISA was successful in 84 samples revealing
6 different LR and 13 different HR types (Figure 2). Dual cervical
HPV infection was found in 16 subjects. HPV-16 (21 out of 109
(19%)) and HPV-35 (11 out of 109 (10%) were most common.
Other prevalent types were HPV-18, -33 and -58 (each 9/109 (8%)),
HPV-31 (8/109 (7%)) and HPV-42 (6/109 (6%)).
DNA sequencing
Human papillomavirus DNA was amplified with the GP5þ/6þ
primers in 11 samples but were negative by ELISA, and therefore
contained HPV types not included in the probe cocktails. These
samples were sequenced with the MY 09/11 primers; five had either
degenerated in storage or would not amplify, two contained
multiple templates and were impossible to sequence, while four
were successfully sequenced and identified but none were infected
with novel types, merely types not included in the ELISA probe
cocktail (Table 2).
DNA sequencing was conducted on samples successfully
identified by ELISA as HPV types associated with HSIL. All
HPV-16 samples sequenced showed DNA homology in the
amplified region with a variant of HPV-16 African type 1 (Af1,
Accession No. AF536180) (Table 2). Both HPV-18 samples
sequenced displayed protein sequence homology to HPV-18
variants from Benin, West Africa (Accession Nos. U45894 and
U45892) (Table 2). HPV-31 from our study showed a number of
polymorphisms and silent mutations compared to the reference
sequence (Accession No. J04353), but insufficient to be a novel
type (Bernard, 2005) (Table 2). All HPV-33 samples sequenced
displayed protein sequence homology to the reference HPV-33
strain (Accession No. M12732) (Table 2). The sequence of HPV-58
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African nation of Mali (Table 2).
Cytology and histology
The overall crude prevalence of cervical precancer was 6.7% (63/
946 adequate smears (95% CI: 5.2–8.4%)), or 6.5% after adjusting
for the under-representation of Wolof women Cytological
abnormalities were confirmed by histology in 55.6% (35/63) of
cases with HSIL present in 2.3% (n¼22; 16 confirmed by
histology), LSIL were found in 3.3% (n¼31; 19 confirmed by
histology) and atypical squamous cells of uncertain significance
(ASCUS) in 1.1% (n¼10). A single case of invasive cervical cancer
was diagnosed by clinical and cytological criteria but the woman
sadly died before the histology could be confirmed; it was included
in the HSIL analysis.
Epidemiology
Risk factors for cervical precancer included age (w
2 P¼0.03) and
cervical HPV infection. Rates of SIL were highest at ages 25–34
years (22 out of 265 (8%)) and 35–44 years (24/268 (9%)),
intermediate at ages 45–54 (9/150 (6%)) and lowest at ages 15–24
(8/263 (3%)). In subjects where both adequate cytology/histology
and HPV analysis were available, 574/612 (93%) had normal
cytology, 38 out of 612 (6%) had SIL and seven out of 612 (1%) had
ASCUS. Of the subjects with normal cytology 525/574 (91%) were
negative for HPV while in those with SIL/ASCUS 20/38 (53%) had
Table 1 Association between cervical HPV infection and socio-demographic, behavioural and infectious factors in the Gambia Reproductive Morbidity
Study
HPV infected/total (%) Crude OR (95%CI) v
2 P-value Adjusted OR
a (95% CI) P-value
b
Age group
15–24 27/184 (15%) 1 1
25–34 22/213 (10%) 0.67 (0.37–1.22) 0.69 (0.37–1.29)
35–44 27/191 (14%) 0.96 (0.54–1.7) 1.10 (0.60–2.04)
45–54 19/122 (16%) 1.07 (0.57–2.02) 0.461 1.13 (0.57–2.25) 0.387
Ethnic group
c
Wolof 20/242 (8%) 1 1
Mandinka 47/328 (14%) 1.86 (1.07–3.22) 0.002 1.76 (1.00–3.09)
Fula 27/129 (21%) 2.94 (1.57–5.48) 2.85 (1.51–5.40) 0.005
Marital status
c
Monogamous 40/266 (15%) 1 1
Polygamous 51/416 (12%) 0.79 (0.50–1.23) 0.84 (0.51–1.36)
Divorced/widowed 3/22 (14%) 0.89 (0.25–3.15) 0.582 0.84 (0.23–3.07) 0.772
Parity
Nulliparous 9/56 (16%) 1 1
Para 1–3 29/205 (14%) 0.86 (0.38–1.94) 0.85 (0.37–1.96)
Para 4–7 40/322 (12%) 0.74 (0.34–1.63) 0.83 (0.33–2.08)
Para 8+ 17/127 (13%) 0.81 (0.34–1.94) 0.871 0.65 (0.23–1.82) 0.844
Sexually active in last 3 months
Yes 62/497 (12%) 1 1
No 21/133 (16%) 1.31 (0.77–2.25) 1.23 (0.70–2.19)
No answer 12/80 (15%) 1.23 (0.63–2.42) 0.549 1.19 (0.58–2.41) 0.731
Genital prolapse
Absent 59/377 (16%) 1 1
Present 36/329 (11%) 0.66 (0.42–1.03) 0.067 0.73 (0.46–1.16) 0.183
HSV2 serology
Negative 53/444 (12%) 1 1
Positive 40/244 (16%) 1.45 (0.93–2.26) 0.102 1.27 (0.78–2.08) 0.343
Current STI
d
Absent 81/605 (13%) 1 1
Present 10/73 (14%) 1.03 (0.51–2.08) 0.941 0.77 (0.36–1.65) 0.494
Endogenous infection
e
Absent 48/328 (15%) 1 1
Present 45/319 (14%) 0.96 (0.62–1.49) 0.848 1.00 (0.63–1.59) 0.985
Anaemia
f
Absent 41/322 (13%) 1 1
Mild 33/272 (12%) 0.95 (0.58–1.54) 0.86 (0.52–1.43)
Moderate/severe 18/96 (19%) 1.58 (0.86–2.91) 0.237 1.45 (0.77–2.73) 0.319
aAdjusted for age group, marital status and ethnic group.
bFrom likelihood ratio test adjusting for age group, marital status and ethnic group.
cFive single women (one had HPV)
and 11 women of other ethnic groups (one had HPV) were excluded from this analysis because of small numbers.
dChlamydia trachomatis, Trichomonas vaginalis, positive
Syphilis serology.
eCandida culture positive, Bacterial vaginosis (Nugent’s criteria).
fAnaemia: mild¼Hbo11 (pregnant) Hbo12 (nonpregnant), moderate/severe¼Hbo9
(pregnant), Hbo10 (nonpregnant).
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types, although the other two were negative for HPV. Among
subjects with HSIL, HPV-16, HPV-33 and HPV-58 were most
common, each found in 3/15 (20%). HPV-16 was found in the
single invasive cancer case. HPV-18, -31, -35, -39 and -45 occurred
once each among subjects with HSIL. Of 30 subjects with LSIL/
ASCUS, seven were infected with HR HPV types; of subjects with
normal cytology 66/576 (12%) had HPV infection.
No associations were found between HPV and other current
sexually transmitted infections (STI) (Table 1). Moderate or severe
anaemia was associated with HPV infection, but not significantly.
Similarly, abnormal vaginal bleeding or discharge, pelvic masses
and body mass index showed no significant associations with HPV
infection. Of 1110 subjects, only 61 (6%) used modern methods of
contraception, too few to examine associations with HPV. Among
socio-demographic factors, only the subject’s ethnic origin was
significantly associated with HPV infection, with Mandinka (14%)
and Fula (21%) women having a higher risk of cervical HPV
infection than Wolof subjects (8%) (Table 1).
DISCUSSION
This first unselected study of cervical HPV and SIL in an
unscreened, rural West-African population of its kind shows
HPV infection to be common at 13.4% (adjusted¼13.0%) with
the majority HR types. Although younger subjects were under-
represented, such an age profile is comparable with other studies.
The high cervical HPV infection prevalence and SIL are in
agreement with Gambian Cancer Registry data (Koulibaly et al,
1997; Bah et al, 2001). Comparable prevalences of 14% have
been observed in two cytologically normal populations in
Senegal, the only nation on which The Gambia borders (Astori
et al, 1999; Xi et al, 2003). A recent study from Nigeria, West
Africa, of an unselected population of similar size typed by GP5þ/
6þ PCR-ELISA, found an HPV prevalence of 26% (Thomas
et al, 2004). However, the population in Thomas et al was urban
(Ibadan, pop. 41M) and the higher HPV prevalence may be
explained by differing sexual behaviour as well as the much
higher prevalence of LR HPV types in the Nigerian study than in
our study.
Much higher HPV prevalence figures have been reported in
recent unselected studies from Eastern and Southern Africa,
ranging from 34% in rural Zimbabwe (Baay et al, 2004) to 44% in
urban Kenya (De Vuyst et al, 2003). Human immunodeficiency
virus (HIV) infection and concomitant immune suppression is
an acknowledged cofactor in the progression of cervical cancer
(Feingold et al, 1990; Moscicki et al, 2004a,b) and such high HPV
prevalence may be due to the high rates of HIV infection in these
regions (UNAIDS, 2004). The Gambia has one of the lowest HIV
infection rates in Africa (Ramsay, 1993, [73]Da Costa, 1994; Schim
van der Loeff et al, 2003). Multiple cervical HPV infection
is common in Africa (Chabaud et al, 1996; Castellsague et al,
2001; Gravitt et al, 2002; Stanczuk et al, 2003; Xi et al, 2003; Baay
et al, 2004) yet we encountered no more than two co-infections,
perhaps because of the low HIV rates in The Gambia (UNAIDS,
2004). Multiple HPV infection have been linked to HIV
immunosuppression (Levi et al, 2002a,b; Moscicki et al, 2004a)
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quintuple HPV infection (Baay et al, 2004).
High oncogenic risk HPV can be detected in 499.7% of high-
grade pre-invasive and invasive cervical lesions (Walboomers et al,
1999). In this study, HPV was found in 87% of subjects with
high-grade lesions, indicating a high degree of accuracy for HPV
detection. Failure to detect HPV in two subjects with HSIL may
be due to integration of viral DNA into their genomic DNA and
the consequent deletion of the target site for the consensus PCR
primers. HPV shows a wide type distribution (Figure 2) (eight
types associated with HSIL), but an even distribution among
subjects. HPV-16, the most common HR type worldwide (Bosch,
1995a,b; Mun ˜oz et al, 2003) is the most common type in this study,
showing the strongest association with precancer.
The HR type HPV-35 was the second most prevalent type (10%)
in this study and meta-analysis of worldwide HPV prevalence
studies shows low overall prevalence of HPV-35 (E2%), even in
Africa (Clifford et al, 2003b). Three selective urban Senegalese
studies found a very low prevalence of HPV-35 ranging from no
HPV-35 positive samples (Astori et al, 1999; Chabaud et al, 1996)
to 1% in the most recent (Xi et al, 2003). Inconsistency between
studies examining Senegal and Gambian populations with over-
lapping ethnic groups, religious practices and trade routes initially
appears incongruous. However, the GP5þ/6þ primers used in
the Gambian study are estimated to be 5000 times more sensitive
in the detection of HPV-35 (Qu et al, 1997) than the MY09/MY11
primer pair used in the Xi and Astori studies. Therefore, the true
HPV-35 prevalence in these Senegalese studies is likely to have
been underestimated. This is supported by other African studies
where HPV-35 is among the four of the most prevalent types in
studies not exclusively using the MY09/11 primer pair for HPV
typing (Castellsague et al, 2001; De Vuyst et al, 2003; Baay et al,
2004; Naucler et al, 2004; Thomas et al, 2004). The Nigerian
population displays a similar distribution of HR types to the
Table 2 Genetic comparison of HPV DNA sequences in the Gambia Reproductive Morbidity Study compared to closest Genbank entries
Homology to Gambian sample(s)
RMS
Gambia
sample
Genbank
accession
number Isolate number (type) Origin
% DNA
similarity
Noncoding
variations
Coding
variations
Samples identified by sequencing
2006D U01532 AE2 (MY9/11) USA 100 0 0
U12481 IS039 (MY9/11) Argentina 99.8 1 0
AF293961 AE2/IS039 (Full) New York, USA 99.5 2 0
AB027021 HPV-82 (Ref.) Japan 89.0 38 8
2712F D21208 HPV-67 (Ref.) NK 98.3 4 3
U12492 (MY09/11) NK 97.8 6 3
2781F U01535 AE1 (MY09/11) USA 99.5 2 0
U21941 HPV-70 (Ref.) Sweden 99.3 3 0
U12476 CP141 (MY09/11) New Mexico, USA 99.1 3 1
U12486 LVX160 (MY09/11) Indigenous Amazonian 99.1 3 1
2919F AF538717 SDL105 (MY09/11) Minesota, USA 99.0 4 0
Y17206 GA115 (MY09/11) Senegal
c 99.8 1 0
M73258 ME180 (Cell Line) NK 98.3 5 2
U45934 IS362 (MY09/11) Germany 97.8 7 2
X67161 HPV-68 (Ref.) NK 93.0 22 7
Samples identified by PCR-ELISA
HPV-16 AF536180 Af1 variant (Full) Africa 100 0 0
U34188 OR7587 (L1) USA 100 0 0
AF472508 Af1 Variant (Full) Africa 99.8 1 0
U34189 OR7632 (L1) USA 99.8 1 0
U34183 OR6106 (L1) USA 99.5 1 1
AF472509 Af2 (Full) Africa 99.3 2 1
AF134178 GU2 (L1) NK 99.3 2 1
U37217 (L1+L2) Zaire
d 99.3 2 1
U34186 OR7145 (L1) USA 99.3 2 1
HPV16R (Ref.) Composite 99.0 4 0
HPV-18 U45894 IS172 (MY09/11) Benin
c 100 0 0
U45892 IS168 (MY09/11) Benin
c 99.8 1 0
U45893 IS768 (MY09/11) Uganda
d 99.3 2 1
0069A
a (MY09/11) Gambia 99.5 2 0
X05015 HPV-18R (Ref.) Brazil 97.6 8 2
HPV-31 U37410 (L1 & L2) NK 99.0 3 1
J04353 HPV-31 (Ref.) NK 98.6 5 1
HPV-33 U45897 IS827 (MY09/11) Guinea
c 99.8 1 0
0184C
b (MY09/11) Gambia 99.8 0 1
M12732 HPV-33 (Ref.) NK 99.8 1 0
HPV-58 U45928 IS417 (MY09/11) Mali 100 0 0
AY101598 Bsb-2 (MY09/11) Brazil 99.7 0 1
U45929 IS404 (MY09/11) Mali 99.2 1 2
D90400 HPV-58 (Ref.) Japan 98.9 1 3
aSample from this study differing in two noncoding bases from the other HPV-18 samples sequenced.
bSample from this study differing in one coding base from the other HPV-
33 samples sequenced.
cWest Africa.
dCentral Africa.
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prevalent types in Nigerian study (Thomas et al, 2004). It thus
appears that HPV-35 is prevalent throughout sub-Saharan Africa
but the extent of this prevalence is underestimated by the use of
the MY09/11 primer pair. This indicates the importance of
methodology in the design of viral epidemiological studies. Of
the 13% (12/93) of samples positive for LR HPV, HPV-42 was most
prevalent, accounting for 50% of LR types and 6% of all HPV
types. This is in contrast to the USA and Europe where HPV-6 and
HPV-11 are the dominant LR types (Mun ˜oz et al, 2003) and most
other African studies, where HPV-53 and -54 are the dominant LR
types (Castellsague et al, 2001; De Vuyst et al, 2003; Xi et al, 2003).
HPV-42 was the most prevalent LR type and overall the most
common HPV type in Nigeria (Thomas et al, 2004), increasing the
overall HPV prevalence, with a LR:HR HPV ratio of 35:65
compared to 11:89 in our Gambian study.
Human papillomavirus is classified into types, subtypes and
variants by comparative DNA homology based upon the L1 outer
capsid. To define a new HPV type it must have less than 90% L1
DNA homology to any previously defined types. Human papillo-
mavirus types can be further characterised into subtypes, 90–98%
L1 DNA homology, and variants (either 498% L1 DNA homology
or oncogene variations). No HPV samples in this study were found
to be novel types after identification by sequencing, although some
were unusual subtypes or variants (Table 2). The DNA sequences
of HPV-16, -18, -33 and -68 revealed HPV variants found by other
African studies. In particular, the Gambian HPV-68 samples are
an exact DNA match to an HPV-68 subtype first isolated from a
study in neighbouring Senegal (Astori et al, 1999). Our study also
confirms the importance of HPV-16 Af1, the most prevalent of the
HPV-16 subtypes in Africa (Yamada et al, 1997). Gambian HPV-18
and HPV-33 variants are homologous to those found in Benin,
Uganda and Guinea (Table 2). Thus, with the non-HPV-16 samples
associated with HSIL in this study, a number of polymorphisms
are observed compared to the reference types but most are
identical or similar to types found in other African studies
(Table 2).
Histologically confirmed cervical neoplasia prevalence in our
study was 6.7% (adjusted¼6.5%). Diagnostic accuracy was
improved by classifying subjects with abnormal cytology but
normal histology as ‘normal cervix’. The prevalence of abnormal
cytology alone was slightly higher at 7.4% (70/946 adequate
smears). Other investigators have used a cytological screening to
identify cervical disease providing a less accurate prevalence of SIL
(Herrero et al, 2000; Castellsague et al, 2001).
In this study, HPV infection was not associated with age,
parity or concurrent STI. The even distribution of HPV prevalence
at different ages is unusual though observed in other developing
countries such as India (Franceschi, 2005) and Argentina
(Matos et al, 2003). Studies from industrialised countries show a
high HPV prevalence among women under 25 years declining with
age (Sellors et al, 2000; Giuliano et al, 2001). This may be explained
by study bias since data are commonly collected from such
highly selective populations as college students or clinic attendees.
Our study, however, concerns a nonselective population with
minimal migration; differing sexual behaviour in different
cultural environments may contribute to the variable age-profiles.
Certain ethnicities were associated with higher risk of cervical
HPV infection in Gambia, a decreased risk being seen in Wolof
women compared with Mandinka and Fula subjects, perhaps
due to differing patterns of sexual behaviour. Another possibility
is genetic variation in susceptibility to HPV infection, for
example, due to differences in HLA types while differences
in female genital cutting (FGC) between the ethnic groups
suggest a further mechanism. The Wolof are the only ethnic
group in our study that do not practice FGC and may thereby
be less susceptible to HPV infection. A previous study of this
group found lower prevalences of HSV-2 (herpes simplex virus)
and bacterial vaginosis among nongenitally cut women (Morison
et al, 2001).
The ideal treatment strategy for this rural Gambian population
would involve the use of a prophylactic vaccine to prevent cellular
viral entry. Current prophylactic vaccine formulations require
three needle injections, cold storage and offer only type specific
protection (Koutsky et al, 2002; Harper et al, 2004). In rural
Gambia with a spread of prevalent HR HPV types, where funding
is short supply, this is impractical. However, vaccines currently in
development include oral based prophylactic vaccines (Baud et al,
2004; Berg et al, 2005; Sasagawa et al, 2005), which will be easier to
store and administer and thus economically viable.
The ethnic groups in our study population have not previously
been studied using these methods. Other studies in African
populations using the same methods to those used in our study (La
Ruche et al, 1998; Bayo et al, 2002; Baay et al, 2004; Naucler et al,
2004; Thomas et al, 2004) show differing LR/HR ratios and disease
associations. This suggests that in addition to HPV infection host
factors are central in the development of cervical cancer. Our
findings strengthen existing data from developing nations,
showing widespread cervical HPV infection of a broader spectrum
than found in industrialised nations with HPV-16 most common.
An effective vaccine for the Gambia must be multivalent and
include the other HR types prevalent in this representative rural
population including HPV-18, -58 and -33. HPV-35 was not found
in high-grade lesions and evidence for its oncogenicity is limited.
However, as the second most prevalent type in this study with
close homology to HPV-16, it may be worth including in any
potential vaccine.
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